Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615399 | 0.86 | DRD2 (0.51) | CHRM4OPRL1CYP3A4CYP2D6 | |
| SCHEMBL3615787 | 0.82 | OPRL1 (0.68) | OPRL1CYP3A4 | |
| SCHEMBL3604592 | 0.79 | CACNA1G (0.58) | OPRL1 | |
| SCHEMBL1859368 | 0.77 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2TP53HRH3 | |
| SCHEMBL27658773 | 0.75 | RAB9A (0.78) | NPC1RAB9ASMN1; SMN2TP53HRH3 | |
| SCHEMBL11646678 | 0.74 | TSHR (0.57) | SMN1; SMN2MEN1KMT2AL3MBTL1CYP2D6 | |
| SCHEMBL4758305 | 0.73 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2TP53HRH3 | |
| SCHEMBL3617803 | 0.73 | OPRL1 (0.68) | OPRL1 | |
| SCHEMBL11649231 | 0.72 | POLB (0.43) | KMT2ACYP2D6 | |
| SCHEMBL4693375 | 0.72 | L3MBTL1 (0.76) | NPC1RAB9ASMN1; SMN2TP53HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128288-A1 | Useful in the treatment of chronic and acute pain. | PURDUE PHARMA L.P. | 2002-09-12 | — | — | US | claimed |
| US-7678809-B2 | Benzimidazole compounds having nociceptin receptor affinity | PURDUE PHARMA L.P. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7456198-B2 | Useful in the treatment of chronic and acute pain. | PURDUE PHARMA L.P. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060264638-A1 | Benzimidazole compounds having nociceptin receptor affinity | EURO-CELTIQUE S.A. (LU) | 2006-11-23 | — | — | US | disclosed |
| US-20020128288-A1 | Useful in the treatment of chronic and acute pain. | PURDUE PHARMA L.P. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264638-A1 | Benzimidazole compounds having nociceptin receptor affinity | OPRL1, OPRK1, OGFRL1 | NPC1 2684/4885RAB9A 3506/4885SMN1; SMN2 1914/4885 |
| US-20020128288-A1 | Useful in the treatment of chronic and acute pain. | OPRL1, OGFRL1, OPRK1 | NPC1 1968/4885RAB9A 2690/4885SMN1; SMN2 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.